In latest setback, another Coherus partner bails out on Amgen biosimilar deal
Just days after Coherus $CHRS was forced to restructure and lay off 51 staffers in the wake of the FDA’s decision to reject its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.